Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) Return on Sales (2020 - 2025)

Tango Therapeutics has reported Return on Sales over the past 6 years, most recently at 1.63% for Q4 2025.

  • Quarterly results put Return on Sales at 1.63% for Q4 2025, up 752.0% from a year ago — trailing twelve months through Dec 2025 was 1.63% (up 147.0% YoY), and the annual figure for FY2025 was 1.63%, up 147.0%.
  • Return on Sales for Q4 2025 was 1.63% at Tango Therapeutics, down from 0.3% in the prior quarter.
  • Over the last five years, Return on Sales for TNGX hit a ceiling of 0.3% in Q3 2025 and a floor of 12.21% in Q2 2025.
  • Median Return on Sales over the past 5 years was 4.03% (2022), compared with a mean of 4.0%.
  • Peak annual rise in Return on Sales hit 752bps in 2025, while the deepest fall reached -1093bps in 2025.
  • Tango Therapeutics' Return on Sales stood at 3.86% in 2021, then dropped by -17bps to 4.53% in 2022, then dropped by -25bps to 5.66% in 2023, then crashed by -62bps to 9.15% in 2024, then surged by 82bps to 1.63% in 2025.
  • The last three reported values for Return on Sales were 1.63% (Q4 2025), 0.3% (Q3 2025), and 12.21% (Q2 2025) per Business Quant data.